Status:
COMPLETED
Safety and Efficacy of Adding AZARGA® Adjunctive to Prostaglandin Therapy
Lead Sponsor:
Alcon Research
Conditions:
Glaucoma
Ocular Hypertension
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
The purpose of this study was to evaluate the safety and efficacy of adding AZARGA® as a single agent to prostaglandin monotherapy in patients with either ocular hypertension or primary open-angle gla...
Detailed Description
This study consisted of 3 study visits (Screening/Baseline, Week 4, and Week 12). Eligible patients self-administered the study medication (AZARGA® Eye Drops), adjunct to their current prostaglandin m...
Eligibility Criteria
Inclusion
- Clinical diagnosis of ocular hypertension, primary open angle (including pigment dispersion) glaucoma in both eyes.
- IOP considered to be safe, in both eyes, in such a way that should assure clinical stability of vision and the optic nerve throughout the study period.
- Treated with, and in the Investigator's judgment demonstrated an inadequate response to, prostaglandin monotherapy for a minimum of 4 weeks at Visit 1. Last dose of prostaglandin instilled correctly to put patient within the dosing cycle at Visit 1.
- At Visit 1, have an IOP of ≥ 20 mmHg in at least one eye and ≤ 35 mmHg in both eyes treated with prostaglandin monotherapy.
- Best corrected visual acuity of 1.0 LogMAR or better in each eye.
- In any eye not qualifying as a study eye, IOP should be able to be controlled on no pharmacologic therapy or on prostaglandin monotherapy alone.
- Willing to sign an informed consent form.
- Able to follow instructions and willing and able to attend required study visits.
- Other protocol-defined inclusion criteria may apply.
Exclusion
- Known medical history of allergy, hypersensitivity or poor tolerance to any component of AZARGA® that is deemed clinically significant in the opinion of the investigator.
- A history of, or at risk for uveitis or cystoid macular edema (CME).
- History of ocular herpes simplex.
- Corneal dystrophies in either eye.
- Concurrent infectious/non infectious conjunctivitis, keratitis or uveitis in either eye (excluding Blepharitis or non-clinically significant conjunctival hyperemia).
- Intraocular conventional surgery or laser surgery in study eye(s) less than 3 months prior to Visit 1.
- Risk of visual field or visual acuity worsening as a consequence of participation in the study, in the investigator's best judgment.
- Progressive retinal or optic nerve disease from any cause apart from glaucoma.
- Use of systemic medications known to affect IOP (e.g. oral beta-adrenergic blockers, alpha-agonists and blockers, angiotensin converting enzyme inhibitors and calcium channel blockers), which have not been on a stable course for 7 days prior to Visit 1 or an anticipated change in the dosage during the course of the study.
- Use of corticosteroids (oral, topical ocular or nasal) within 30 days of Visit 1 and during the course of the study.
- Bronchial asthma or a history of bronchial asthma, bronchial hyper reactivity, or severe chronic obstructive pulmonary disease that would preclude the safe administration of a topical beta-blocker.
- History of severe allergic rhinitis.
- A condition, which in the opinion of the principal investigator, would interfere with optimal participation in the study, or which would present a special risk to the subject.
- Use of any systemic carbonic anhydrase inhibitors (CAI) (e.g. methazolamide \[Neptazane\], acetazolamide \[Diamox\]).
- Severely impared renal function.
- History of an allergy to sulphonamides.
- Bronchial asthma or a history of bronchial asthma, bronchial hyper reactivity, severe allergic rhinitis or severe chronic obstructive pulmonary disease that would preclude the safe administration of a topical beta-blocker.
- Pregnant, lactating, or of childbearing potential and not using a reliable method of birth control.
- Any clinically significant, serious, or severe medical condition.
- Participation in any other investigational study within 30 days prior to the screening/baseline visit.
- Other protocol-defined exclusion criteria may apply.
Key Trial Info
Start Date :
March 1 2011
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2013
Estimated Enrollment :
47 Patients enrolled
Trial Details
Trial ID
NCT01263444
Start Date
March 1 2011
End Date
April 1 2013
Last Update
May 20 2014
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.